珠海润都制药股份有限公司 投资者关系活动记录表 证券简称：润都股份 证券代码：002923 编号：2018-002 | --- | --- | --- | |-------------------------|----------------------------|--------------------------------------------------| | | | | | | □ | 特定对象调研 □ 分析师会议 | | | □媒体采访 □ 业绩说明会 | | | 投 资 者 关 | □ 新闻发布会 □ 路演活动 | | | 系 活 动 类 | □ 现场参观 | | | 别 | √其他（2018 | 年广东辖区上市公司投资者关系管理月活动投资者集体 | | | 接待日） | | | 参 与 单 位 名 称 及 人 | 公司投资者 | | | 员姓名 | | | | 时间 | 2018 年 5 月 3 | 日 15:00-16:30 | | 地点 | 全景•路演天下（ | http://rs.p5w.net ） | | 上 市 公 司 | 副总经理、董事会秘书：曾勇 | | | 接 待 人 员 ...

珠海润都制药股份有限公司 投资者关系活动记录表 证券简称：润都股份 证券代码：002923 编号：2018-001 | --- | --- | --- | |-------------------------|-------------------------|----------------------------------------------------| | | □ | 特定对象调研 □ 分析师会议 | | | □媒体采访 | √ 业绩说明会 | | 投资者关系活 | □ | 新闻发布会 □ 路演活动 | | 动类别 | □ 现场参观 | | | | □ | 其他（请文字说明其他活动内容） | | 参与单位名称 及人员姓名 | 参与公司 2017 | 年年度报告网上业绩说明会的不特定投资者 | | 时间 | 2018 年 5 月 2 | 日（星期三）下午 15:00-17:00 | | | | | | 地点 | 全景•路演天下（ | http://rs.p5w.net ） | | | 董事长：李希先生 | | | | 董事/总经理：陈新民先生 | | | 上市公司接待 | | 副总经理/董事会秘书 ...

珠海润都制药股份有限公司 投资者关系活动记录表 证券简称：润都股份 证券代码：002923 编号：2018-03 | --- | --- | --- | |--------------------|-------------------------|-----------------------------------------------| | | | | | | √ | 特定对象调研 □ 分析师会议 | | 投 资 者 关 | □ 媒体采访 □ 业绩说明会 | | | 系 活 动 类 | □ 新闻发布会 □ 路演活动 | | | 别 | □ 现场参观 | | | | □其他 | | | 参 与 单 位 | | 长城证券股份有限公司：医药行业研究员 彭学龄 | | 名 称 及 人 员姓名 | | 博时基金管理有限公司：股票投资部基金经理 尹哲 | | 时间 | 2018 年 6 月 13 | 日（星期三）上午 10： 45-12:00 | | 地点 | 公司行政楼二楼会议室 | | | 上 市 公 司 | 董事会秘书：曾勇 | | | 接 待 人 员 姓名 | 证券事务代表：徐维 | | | --- | ...

珠海润都制药股份有限公司 投资者关系活动记录表 证券简称：润都股份 证券代码：002923 编号：2018-04 | --- | --- | --- | |--------------------|------------------------|--------------------------------------------| | | √ | 特定对象调研 □ 分析师会议 | | 投 资 者 关 | | □媒体采访 □ 业绩说明会 | | 系 活 动 类 | □新闻发布会 □ 路演活动 | | | 别 | □现场参观 | | | | □其他 | | | 参 与 单 位 | | 宁波市荣腾投资管理有限公司：总经理 赵堃 | | 名 称 及 人 员姓名 | | 南京彤天基金管理有限公司：研究员 王公越 | | 时间 | 2018 年 11 月 | 19 日（星期一）上午 10：30-11:30 | | 地点 | 公司行政楼二楼会议室 | | | 上 市 公 司 | 董事会秘书：曾勇 | | | 接 待 人 员 | | | | 姓名 | 证券事务代表：徐维 | | | 投 资 者 关 | | 一、公司董事 ...

编号：2021-01 证券代码：002923 证券简称：润都股份 珠海润都制药股份有限公司投资者关系活动记录表 | --- | --- | --- | |------------------------------|----------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

证券代码： 002923 证券简称：润都股份 珠海润都制药股份有限公司投资者关系活动记录表 编号：2022-002 | --- | --- | --- | |-------------------------|-------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | 投资者关系活动 \n类别 | □ 特定对象调研 \n□ 媒体采访 \n□ 新闻发布会 现场参观 \n□ √ 其他（ 2022 | □ 分析师会议 \n □ ...

珠海润都制药股份有限公司 2022 年第三季度报告 证券代码：002923 证券简称：润都股份 公告编号：2022-056 珠海润都制药股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第三季度报告是否经过审计 □是 否 1 珠海润都制药股份有限公司 2022 年第三季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 是 □否 追溯调整或重述原因 其他原因 | | 本报告期 | | 上年同期 | 本报告期 比上年同 | 年初至报 | 上年同期 | | 年初至报 告期末比 上年同期 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | ...

证券代码：002923 证券简称：润都股份 公告编号：2022-052 珠海润都制药股份有限公司 关于参加2022年广东辖区上市公司投资者 网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，珠海润都制药股份有限公司（以下简称"公 司"）将参加由中国证券监督管理委员会广东监管局、广东上市公司协会共同举办 的 2022 年广东辖区上市公司投资者网上集体接待日活动。 现将有关事项公告如下： 本次投资者网上集体接待日活动将在深圳市全景网络有限公司提供的网上平 台 ， 采 取 网 络 远 程 的 方 式 举 行 。 投 资 者 可 登 录 " 全景路演 " 网 站 （http://rs.p5w.net）参与本次活动，网上互动交流时间为 2022 年 9 月 22 日（星 期四）15:50 至 16:50。 届时公司董事长陈新民先生、董事兼总经理刘杰先生、董事会秘书（代行）兼 副总经理财务总监石深华先生将通过网络在线交流形式与投资者进行沟通交流，欢 迎广大投资者积极参与。 特此公告。 珠海润都制药股份有限公司 董事会 ...

Financial Performance - The company reported a revenue of 1.2 billion RMB for the first half of 2022, representing a year-on-year increase of 15%[1]. - The net profit attributable to shareholders was 300 million RMB, up 20% compared to the same period last year[1]. - The company achieved operating revenue of CNY 658.87 million, representing a 14.68% increase compared to the same period last year[22]. - Net profit attributable to shareholders reached CNY 75.10 million, up 16.28% year-on-year[22]. - The net profit after deducting non-recurring gains and losses was CNY 69.32 million, reflecting a 16.43% increase from the previous year[22]. - The company reported an operating profit of CNY 84.22 million, which is a 19.59% increase compared to the same period last year[32]. - Basic earnings per share for the first half of 2022 were CNY 0.31, consistent with the previous year[22]. - The company’s net profit growth rate for 2021 did not meet the conditions for the release of certain restricted shares, leading to the repurchase of 1,671,950 shares from 190 incentive targets[158]. - The company reported a total comprehensive income of CNY 86,456,016.55, compared to CNY 69,017,148.98 in the previous year, indicating a growth of 25.3%[199]. Market Expansion and Product Development - User data showed an increase in active users by 25%, reaching 5 million by the end of June 2022[1]. - The company plans to launch three new products in the second half of 2022, targeting a market expansion of 30% in the new segments[1]. - The company is focused on expanding its international market presence, contributing to the growth in raw materials and intermediates sales[31]. - The company is investing in the expansion of high-end raw material drug production, with a total investment of ¥8,587,872 planned[77]. - The company has launched 9 enteric-coated and sustained-release formulation products, with multiple projects under research[58]. Research and Development - Research and development expenses increased by 10% to 150 million RMB, focusing on innovative drug formulations[1]. - R&D investment amounted to 4,352.25 million CNY, reflecting a year-on-year increase of 9.81%[34]. - The company submitted 13 patent applications during the reporting period, including 4 invention patents and 4 utility model patents[36]. - Research and development expenses increased to ¥43,522,530.48, up from ¥39,634,607.06, reflecting a focus on innovation[194]. - Research and development expenses increased to CNY 44,624,430.25, compared to CNY 40,946,050.86 in the previous year, reflecting a growth of 9.2%[198]. Financial Management and Liabilities - The total liabilities increased by 10.73% to CNY 882.84 million, resulting in a debt-to-asset ratio of 44.23%, up 2.48 percentage points[31]. - The company reported a significant increase in prepayments, which rose to CNY 43,290,546.50 from CNY 23,020,291.88, representing an increase of approximately 88.5%[186]. - Total liabilities reached CNY 882,839,860.10, up from CNY 797,282,506.70, indicating an increase of about 10.7%[187]. - Long-term borrowings increased significantly to CNY 367,413,340.00 from CNY 250,000,000.00, marking a rise of about 46.9%[187]. - The company reported a net cash flow from operating activities of -¥3,503,174.12, a significant decrease of 123.61% compared to ¥14,835,526.91 in the previous year[66]. Regulatory and Compliance Issues - The company is facing regulatory challenges that may impact its product approval timelines, which are being actively managed[1]. - The company emphasizes strict adherence to GMP standards across all processes to ensure product quality and compliance with new regulations[89]. - The company has established a comprehensive safety management system, achieving no major safety incidents during the reporting period[37]. - The company has implemented measures to ensure wastewater treatment meets the Class A standard as per national regulations, achieving compliance with GB18918-2002[106]. Environmental and Social Responsibility - The company has implemented effective environmental protection measures, ensuring that wastewater treatment meets the standards of the Guangdong Province[102]. - The company has made donations totaling CNY 126,800 to support rural revitalization and improve living conditions in Tibet[121]. - A donation of CNY 95,870 worth of self-produced medicines was made to enhance the medical skills of rural doctors, contributing to poverty alleviation efforts[121]. - The company has compiled its first sustainability report for 2021, focusing on environmental, health, labor, and ethical management[122]. - The company actively engages in social responsibility, aiming to benefit a wide range of stakeholders including shareholders, employees, and the community[115]. Shareholder and Equity Management - The company will not distribute cash dividends or issue bonus shares for this fiscal year[1]. - The company distributed a cash dividend of RMB 4.00 per 10 shares, totaling RMB 74,271,700.00, based on a total share capital of 185,679,250 shares[43]. - The company completed the repurchase and cancellation of 30,400 restricted stocks as part of its stock incentive plan[96]. - The total number of ordinary shareholders at the end of the reporting period was 17,302[169]. - Major shareholders include Li Xi and Chen Xinmin, each holding 29.85% of the shares, totaling 72,047,130 shares[169].

Financial Performance - The company's operating revenue for 2021 was approximately ¥1.19 billion, a decrease of 5.01% compared to ¥1.25 billion in 2020[20]. - Net profit attributable to shareholders for 2021 was approximately ¥139.77 million, an increase of 2.87% from ¥135.86 million in 2020[20]. - The net profit after deducting non-recurring gains and losses was approximately ¥126.63 million, reflecting an increase of 11.33% from ¥113.75 million in 2020[20]. - The net cash flow from operating activities was approximately ¥205.91 million, a decrease of 17.75% compared to ¥250.35 million in 2020[20]. - Total assets at the end of 2021 reached approximately ¥1.91 billion, an increase of 26.14% from ¥1.51 billion at the end of 2020[20]. - The net assets attributable to shareholders at the end of 2021 were approximately ¥1.11 billion, up 7.12% from ¥1.04 billion at the end of 2020[20]. - The basic earnings per share for 2021 was ¥0.76, an increase of 2.70% from ¥0.74 in 2020[20]. - The weighted average return on equity for 2021 was 13.06%, a decrease of 0.75% from 13.81% in 2020[20]. - The company reported a total of ¥16.76 million in government subsidies related to normal business operations in 2021, down from ¥26.88 million in 2020[25]. Risk Management and Governance - The company has detailed various risks and countermeasures in its annual report, ensuring transparency for investors[4]. - The company emphasizes the importance of accurate financial reporting, with key personnel affirming the completeness and truthfulness of the financial statements[3]. - All board members attended the meeting to review the annual report, indicating strong governance practices[4]. - The company has not identified any significant risks that could materially affect its operations during the reporting period[4]. - The company's governance and internal control measures have been strengthened, including the management of 1,839,500 shares of restricted stock for 212 employees[65]. - The company has established a complete corporate governance structure, including a shareholders' meeting, board of directors, supervisory board, and management team, ensuring compliance with relevant laws and regulations[126]. - The actual governance situation of the company aligns with the requirements of the "Code of Corporate Governance for Listed Companies," with no significant discrepancies identified[127]. - The company maintains independence in assets, personnel, finance, organization, and business from its controlling shareholders, ensuring a complete operational system[128]. Research and Development - The company invested CNY 92.14 million in R&D during 2021, focusing on both independent and collaborative development efforts[55]. - The company achieved multiple R&D milestones, including the DMF registration for new drugs such as Carvedilol and Ibuprofen, and completed the technical review for the active pharmaceutical ingredient (API) of Right Levosimendan[56]. - The company submitted 62 patent applications in 2021, including 37 invention patents, and was awarded 30 new patents[58]. - The company is committed to improving its research and development efforts to address the growing demand for innovative and accessible medications[31]. - The company continues to focus on the development of innovative drug formulations and controlled-release technologies[117]. Production and Operations - The company operates several wholly-owned subsidiaries, enhancing its operational capabilities and market reach[11]. - The company has established a complete procurement, production, and sales system, ensuring compliance with GMP standards for both formulation and raw material production[38]. - The company has implemented a contract manufacturing model (CMO) to enhance production capabilities and meet specific client needs[40]. - The company is investing in a new production capacity project for oral solid preparations, targeting an annual output of 6 billion tablets, expected to be operational in 2022[119]. - The company is advancing the construction of the high-end raw material production base in Jingmen, focusing on GMP management and safety production standards[120]. Market Strategy and Sales - The sales strategy combines professional academic promotion with commercial distribution and regional control, enhancing market reach and product availability[39]. - The company aims to become a leading enterprise in the production of microtablet formulations and antihypertensive drugs, aligning with national health strategies[32]. - The company is focused on expanding its market presence and enhancing its product offerings through strategic initiatives[141]. - The company plans to enhance its raw material and pharmaceutical intermediate sales through long-term strategic partnerships and increased market coverage[115]. Environmental and Social Responsibility - The company emphasizes the importance of environmental protection and safety production, implementing systematic and standardized management practices[119]. - The company has implemented effective environmental management measures to treat wastewater, ensuring compliance with the Guangdong Province water pollution discharge standards[200]. - The company has not reported any major environmental violations during the reporting period[199]. - The company is classified as a key pollutant discharge unit by environmental protection authorities[199]. Shareholder Returns and Dividends - The company plans to distribute a cash dividend of 4.00 CNY per 10 shares (including tax) to all shareholders, with no bonus shares issued[4]. - The company has established a clear profit distribution policy, focusing on long-term sustainable development and ensuring reasonable returns for shareholders[172]. - The distributable profit for the company was 519,952,682.64 CNY, after accounting for a statutory surplus reserve of 10% from the net profit of 143,831,378.57 CNY for the year[175]. - The company reported a cash dividend of 4.00 CNY per 10 shares (including tax), with a total cash dividend amounting to 74,271,700 CNY, which represents 100% of the total profit distribution[173]. Employee Management and Training - The total number of employees at the end of the reporting period was 1,594, with 1,136 in the parent company and 458 in major subsidiaries[162]. - The company implemented a comprehensive employee compensation policy consisting of fixed salary, overtime pay, work allowances, seniority allowances, living allowances, holiday bonuses, and year-end performance bonuses[164]. - In 2021, the company conducted 20 new employee training sessions with a total of 353 participants and 2,063 internal training sessions with 55,038 participants[170]. Future Outlook - The company aims to achieve a revenue of CNY 1,442.31 million in 2022, representing a growth of 21.21% compared to the previous year[115]. - The projected net profit for 2022 is CNY 146.34 million, an increase of 4.70% year-over-year[115]. - The company is accelerating the R&D of new raw materials and aims to register products in the EU, the US, Japan, and South Korea[118].